Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.

Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.

Pediatr Blood Cancer. 2014 Oct;61(10):1867-70. doi: 10.1002/pbc.24927. Epub 2014 Jan 4.

PMID:
24391119
2.

Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.

Cattelani S, Defferrari R, Marsilio S, Bussolari R, Candini O, Corradini F, Ferrari-Amorotti G, Guerzoni C, Pecorari L, Menin C, Bertorelle R, Altavista P, McDowell HP, Boldrini R, Dominici C, Tonini GP, Raschellà G, Calabretta B.

Clin Cancer Res. 2008 Jun 1;14(11):3248-53. doi: 10.1158/1078-0432.CCR-07-4725.

3.

Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.

Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Haupt R, Fronza G, Tonini GP.

Eur J Cancer. 2008 Nov;44(17):2634-9. doi: 10.1016/j.ejca.2008.08.018. Epub 2008 Oct 1.

PMID:
18835771
4.

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.

Kaderi MA, Mansouri M, Zainuddin N, Cahill N, Gunnarsson R, Jansson M, Kimby E, Aleskog A, Lundin J, Glimelius B, Melbye M, Juliusson G, Jurlander J, Rosenquist R.

Leuk Res. 2010 Mar;34(3):335-9. doi: 10.1016/j.leukres.2009.06.006. Epub 2009 Jul 1.

PMID:
19573916
5.

MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.

Dong HJ, Fang C, Fan L, Zhu DX, Wang DM, Zhu HY, Zhuang Y, Miao KR, Liu P, Xu W, Li JY.

Int J Cancer. 2012 May 1;130(9):2054-61. doi: 10.1002/ijc.26222. Epub 2011 Aug 9.

6.

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.

Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarrà GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G.

Pediatr Blood Cancer. 2009 Oct;53(4):576-83. doi: 10.1002/pbc.22132.

PMID:
19526525
7.

MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.

Parodi S, Perfumo C, Garaventa A, Inga A, Mazzocco K, Defferrari R, Tonini GP, Fronza G, Haupt R.

Pediatr Blood Cancer. 2010 Aug;55(2):267-72. doi: 10.1002/pbc.22477.

PMID:
20232446
8.

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.

Clin Cancer Res. 2007 Jul 15;13(14):4123-9.

9.

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.

Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I.

J Clin Oncol. 2008 May 10;26(14):2252-7. doi: 10.1200/JCO.2007.11.5212.

PMID:
18467716
11.

MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.

Akkiz H, Sümbül AT, Bayram S, Bekar A, Akgöllü E.

Cancer Epidemiol. 2010 Aug;34(4):448-52. doi: 10.1016/j.canep.2010.04.008. Epub 2010 May 5.

PMID:
20447891
12.

MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.

Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Lee CP, Lin SF.

Mol Carcinog. 2014 Dec;53(12):951-9. doi: 10.1002/mc.22061. Epub 2013 Jul 2.

PMID:
23818300
13.

MDM2 SNP309 polymorphism is associated with colorectal cancer risk.

Wang W, Du M, Gu D, Zhu L, Chu H, Tong N, Zhang Z, Xu Z, Wang M.

Sci Rep. 2014 May 6;4:4851. doi: 10.1038/srep04851.

14.

MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.

Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M.

Clin Cancer Res. 2006 Aug 15;12(16):4867-71.

15.

Association of breast cancer outcome with status of p53 and MDM2 SNP309.

Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S.

J Natl Cancer Inst. 2006 Jul 5;98(13):911-9.

PMID:
16818855
16.

Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.

Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.

Brain Res. 2008 Mar 10;1198:16-20. doi: 10.1016/j.brainres.2008.01.027. Epub 2008 Jan 18.

PMID:
18262501
17.

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.

Willander K, Ungerbäck J, Karlsson K, Fredrikson M, Söderkvist P, Linderholm M.

Eur J Haematol. 2010 Sep;85(3):251-6. doi: 10.1111/j.1600-0609.2010.01470.x. Epub 2010 May 14.

PMID:
20491880
18.

A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.

Nan H, Qureshi AA, Hunter DJ, Han J.

Cancer Causes Control. 2009 Mar;20(2):171-9. doi: 10.1007/s10552-008-9231-9. Epub 2008 Sep 24.

19.

Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Walsh CS, Miller CW, Karlan BY, Koeffler HP.

Gynecol Oncol. 2007 Mar;104(3):660-4. Epub 2006 Nov 21.

PMID:
17123590
20.

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.

Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC, Lee YJ.

Oncol Rep. 2011 Jun;25(6):1755-63. doi: 10.3892/or.2011.1254. Epub 2011 Apr 8.

PMID:
21479369

Supplemental Content

Support Center